Many studies have analyzed the diagnostic value (i.e., sensitivity and specificity) of these two IHC assays for detecting HER2-positive BC by comparing IHC results to the HER2 gene amplification status determined by ISH assays [15–17]. Here, ERBB2 is linked to breast cancer.